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PARDIOVASCULAR GENOMIC MEDICINE
ew Paradigms in Cardiovascular Medicine
merging Technologies and Practices: Perioperative Genomics
ihai V. Podgoreanu, MD,* Debra A. Schwinn, MD*†‡§
urham, North Carolina
Considerable progress has been made in understanding the pathophysiology of perioperative
stress responses and their impact on the cardiovascular system; however, researchers are just
beginning to unravel genetic and molecular determinants that predispose to increased risk for
postoperative cardiovascular adverse events. A new field, coined perioperative genomics, aims
to apply functional genomic approaches to uncover the biological reasons why similar patients
can have dramatically different clinical outcomes after surgery. For the perioperative physician,
such findings may soon translate into prospective risk assessment incorporating genomic
profiling of markers important in inflammatory, thrombotic, vascular, and neurologic responses
to perioperative stress, with implications ranging from individualized additional pre-operative
testing and physiological optimization, to perioperative decision-making, choice of monitor-
ing strategies, and critical care resource utilization. We review current knowledge regarding
genomic technologies in perioperative cardiovascular disease characterization and outcome
prediction, as well as discuss future trends/challenges for translating integrated “omic”
information into daily clinical management of the surgical patient. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.0402005;46:1965–77) © 2005 by the American College of Cardiology Foundation
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perioperative care of surgical patients remains a critical
omponent of modern medicine, requiring comprehensive
nd increasingly multidisciplinary approaches. Cardiologists
re intimately involved in estimating risk for patients with
ardiovascular disease of developing postoperative compli-
ations such as myocardial infarction, arrhythmias, stroke,
r sudden death. This review discusses unique characteris-
ics of perioperative injury and highlights current and future
pplications of genomic technologies in perioperative car-
iovascular disease characterization, risk assessment, and
utcome prediction, as well as identification and validation
f novel therapeutic targets and strategies.
ENETIC VARIABILITY AND PERIOPERATIVE
ARDIOVASCULAR RISK ASSESSMENT
everal pre-operative cardiac risk assessment tools have been
eveloped to guide perioperative management of patients at
igh risk for cardiovascular morbidity. For noncardiac sur-
ery, historical risk indexes proposed by Goldman, Detsky,
nd Lee were found to have only modest positive predictive
alue. Current standards for pre-operative cardiac evalua-
ion support the use of noninvasive cardiac tests to improve
erioperative risk stratification (1), but predictive value
emains 25% (2). Similarly, a variety of risk stratification
ystems have been proposed for cardiac surgical patients
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Surgery, Duke University Medical Center, Durham, North Carolina; and the
Center for Genomic Medicine, Duke Institute for Genome Science and Policy,
urham, North Carolina. Supported in part by grants AG17556 and HL075273 (to
r. Schwinn) from the National Institutes of Health and grant 0120492U (to Dr.
odgoreanu) from the American Heart Association..c
Manuscript received June 21, 2005; revised manuscript received August 5, 2005,
ccepted August 17, 2005.inked to mortality, serious nonfatal morbidity, resource
tilization, and patient satisfaction (3). Prospective evalua-
ion of such severity-adjusted models reveal marked discrep-
ncies in predicting individual outcomes, as well as system-
tic biases in over/under-prediction for subgroups of
atients (4). Due to lack of precision in individual classifi-
ation, the search for novel risk factors predicting periop-
rative cardiovascular adverse events is important.
The need for improved perioperative risk profiling is
urther justified by a worrisome growing surgical burden,
wing to accelerated population aging and increased reli-
nce on surgery for disease treatment. Over 40 million patients
ndergo surgery annually in the U.S., resulting in costs of
450 billion per year (5). With approximately one-third of
urgical patients 65 years of age and 40% having athero-
clerosis risk factors (5), 1.25 million perioperative car-
iovascular complications occur annually, resulting in an
dditional $25 billion in health care expenditures (6). It is
rojected that by 2020 the number of surgeries will increase
y 25%, associated costs by 50%, and likelihood of
therosclerotic-related cardiac, cerebral, and renal compli-
ations by 100% (6).
One hallmark of perioperative medicine is striking vari-
bility in patient response(s) to surgical stress, anesthetic
gents, hemodynamic challenges, and the pharmacopoeia
sed in the perioperative period. Current risk stratification
ased on patient demographics, comorbidities, physiologic
eserve, and procedural variables explains only a small part
f observed variability in incidence of perioperative compli-
ations. Evidence is accumulating that genetic variations, or
olymorphisms, can significantly affect an individual’s sus-
eptibility to adverse postoperative events (7–9). A new
fi
g
u
o
W
C
a
r
p
i
e
v
p
r
c
e
p
e
r
r
g
g
c
t
a
c
a
d
g
(
t
s
f
r
f
p
s
a
F
p
T
I
L
1966 Podgoreanu and Schwinn JACC Vol. 46, No. 11, 2005
Genetics of Perioperative Outcomes December 6, 2005:1965–77eld, coined perioperative genomics, aims to apply functional
enomic approaches to uncover the biological mechanisms
nderlying why similar patients have dramatically different
utcomes after surgery (10).
HY PERIOPERATIVE GENOMICS?
ommon chronic diseases like atherosclerosis, coronary
rtery disease (CAD), hypertension, and diabetes, as well as
esponses to injury, drugs, and non-pharmacological thera-
ies, are genetically complex, characteristically involving
nterplay of many susceptibility genes and environmental
xposures (Fig. 1). In the perioperative period, patients with
arious burdens of complex comorbid conditions are ex-
osed to “controlled trauma” in the operating room envi-
onment, consisting of surgical injury, anesthesia, pharma-
ologic interventions, and, in the case of cardiac surgery,
xtracorporeal circulation. As an environmental stimulus,
erioperative injury can be characterized as: 1) robust and
xtreme; 2) multifactorial (i.e., outcomes are the cumulative
esult of both direct initial operative injury and the host’s
esponses to injury, both interacting with an individual’s
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
APOE  apolipoprotein E
AR  adrenergic receptor
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CPB  cardiopulmonary bypass
FVL  factor V Leiden
HSP  heat shock protein
IL  interleukin
MACE  major adverse cardiac events
PAI-1  plasminogen activator inhibitor-1
PMI  perioperative myocardial infarction
PoAF  postoperative atrial fibrillation
SNP  single nucleotide polymorphismigure 1. Perioperative outcomes are complex traits, characteristically involvin
roduce a final clinical phenotype (presence/absence and severity of an adverseenetic background); 3) quantifiable (e.g., for cardiac sur-
ery, duration of cardiopulmonary bypass [CPB] and aortic
ross-clamping, number of coronary bypass grafts, volume,
ype and route of cardioplegia, perioperative medications,
nd so on); 4) defined onset of exposure; and 5) defined time
ourse, usually shorter than for common chronic diseases,
lthough in some cases predictive of future natural history of
isease (e.g., cognitive decline).
Characteristic phenotypes studied by perioperative
enomics include immediate postoperative adverse events
incidence/severity of organ dysfunction), as well as long-
erm outcomes (Table 1). Overall, an individual’s genetic
usceptibility to adverse perioperative events stems not only
rom genetic contributions to the development of comorbid
isk factors (like CAD) during the patient’s lifetime, but also
rom genetic variability in specific biological pathways
articipating in pathophysiological events during and after
urgery. Thus, the term perioperative genomics is justified by
combination of unique environmental insults and postop-
able 1. Categories of Perioperative Phenotypes
mmediate perioperative
outcomes
In-hospital mortality
Perioperative myocardial infarction
Low cardiac output syndrome
Perioperative arrhythmias
Postoperative bleeding
Acute postoperative stroke
Acute renal injury
Acute lung injury/prolonged postoperative
mechanical ventilation
Acute allograft dysfunction/rejection
Postoperative sepsis
Variability in response to perioperative drugs
Intermediate phenotypes (plasma biomarker
levels)
ong-term postoperative
outcomes
Event-free survival/major adverse cardiac
events
Progression of vein graft disease
Chronic allograft dysfunction/rejection
Neurocognitive dysfunction
Quality of lifeg multiple gene-gene interactions and gene-environment interactions to
event). CPB  cardiopulmonary bypass; OR  operating room.
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December 6, 2005:1965–77 Genetics of Perioperative Outcomesrative phenotypes that characterize surgical and critically ill
atient populations.
ERIOPERATIVE GENOMICS STUDIES:
AJOR FINDINGS
lthough several important genetic determinants of com-
lex cardiovascular outcomes like myocardial infarction (11)
nd stroke (12) have been identified using genome-wide
inkage analysis, such studies rely on data from multigen-
ration families, something impractical in studies investi-
ating perioperative outcomes. Furthermore, perioperative
dverse events likely involve multiple susceptibility markers,
ach of modest importance, thereby limiting application of
inkage analysis. Thus, most discoveries in perioperative
enomics derive from association studies examining specific
enetic polymorphisms in population-based samples of
nrelated diseased individuals and appropriately matched
naffected controls. Candidate genes are first selected based
n a priori hypotheses about potential etiological roles in
dverse outcomes, current understanding of pathophysio-
ogic processes from literature reviews, biochemical/
hysiologic pathway analysis, and expert opinion (13). Fur-
her candidate genes are identified in more unbiased ways
sing microarray gene expression profiling in human tissues
nd surgical animal models. Growing evidence suggests that
ariability in gene expression levels underlies susceptibility
o complex disease and is determined by regulatory poly-
orphisms affecting transcription, splicing, and translation
fficiency in a tissue- and stimulus-specific manner (14).
hus, in the current conceptual framework, identification of
isease-modifying genes involves integrating data on DNA
equence variation and gene expression variation in well-
henotyped surgical patient populations.
Several reciprocally interactive complex biological systems
re involved in perioperative organ injury (Fig. 2). Specific
enetic variants in these pathways have been associated with
arious organ-specific adverse outcomes, including myocar-
ial ischemia (15), postoperative arrhythmias (16), vein
raft restenosis (17), transplant rejection (18), renal com-
romise (19,20), neurocognitive dysfunction (21,22), stroke(
igure 2. Biological systems and mechanistic pathways genetically associ-
ted with perioperative adverse events.23), and death (24,25), as well as broader systemic abnor-
alities mechanistically involved in perioperative complica-
ions like bleeding (26,27), thrombosis (28), inflammatory
esponses and severe sepsis (29), and alterations in vascular
eactivity (30). To increase clinical relevance for the prac-
icing cardiologist, we summarized these studies by specific
utcome while highlighting candidate genes in relevant
echanistic pathways (Tables 2 and 3).
erioperative myocardial injury. Adverse cardiovascular
vents persist as serious complications after anesthesia and
urgery, with mortality after perioperative myocardial in-
arction (PMI) of 40% to 50% (31). Similarly, despite ad-
ances in surgical, cardioprotective, and anesthetic tech-
iques, incidence of PMI after cardiac surgery ranges from
% to 15% (32) and alters long-term survival. Reports from
nimal models, linkage, twin, and population association
tudies reveal genetic influences in incidence and progres-
ion of CAD; heritability of death from CAD is as high as
.57 (33), and hazardous patterns of angiographic CAD
left main and proximal disease), known major risk factors
or perioperative cardiovascular complications, are also highly
eritable (34). Similarly, genetic susceptibility to myocardial
nfarction is established (11,35). Although these studies do
ot directly address heritability of adverse perioperative
yocardial events, they suggest a strong genetic contribu-
ion to risk of adverse cardiovascular outcomes in general.
A paucity of studies exists directly relating genetic risk
actors to adverse perioperative myocardial outcomes, mainly
fter coronary artery bypass grafting (CABG) (17,36,37). In
he setting of cardiac surgery, PMI involves three major
onverging pathophysiologic processes (Fig. 3). In non-
ardiac surgery, pathophysiology of PMI is not so clearly
nderstood, but a combination of two mechanisms appears
redominant: 1) plaque rupture and coronary thrombosis
riggered by perioperative endothelial injury from catechol-
mine surges, proinflammatory and prothrombotic states;
nd 2) prolonged stress-induced ischemia and tachycardia in
he context of compromised perfusion. Extensive genetic
ariability exists in each of these mechanistic pathways, which
ay combine to modulate magnitude of myocardial injury.
NFLAMMATORY GENE POLYMORPHISMS AND POSTOPERA-
IVE MYOCARDIAL OUTCOMES. Genetic variants affecting
nflammatory responses have been identified. Polymor-
hisms in the interleukin-6 (IL6) gene promoter signifi-
antly increase inflammatory response to cardiac surgery
ith CPB (38) and are associated with length of hospital-
zation after CABG (39). Both apolipoprotein E (APOE)
enotype (40) and several single nucleotide polymorphisms
SNP) in tumor necrosis factor genes have been associated
ith proinflammatory effects in patients undergoing CPB
41). Conversely, an SNP-modulating expression of anti-
nflammatory cytokine IL10 in response to CPB has been
ssociated with postoperative cardiovascular dysfunction
42). Recently, Shaw et al. (43) reported an association
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Genetics of Perioperative Outcomes December 6, 2005:1965–77etween SNPs in two inflammatory genes (IL6 and tumor
ecrosis factor-alpha [TNFA]) and incidence of postopera-
ive complications (a composite outcome that included
MI) after non-cardiac surgery (lung resection for cancer).
aken together, an exaggerated proinflammatory response
o surgical stress appears to correlate with enhanced adverse
ostoperative events.
OAGULATION VARIABILITY AND PERIOPERATIVEMYOCAR-
IAL OUTCOMES. The acute-phase response to surgery is
haracterized by increased fibrinogen concentration, platelet
dhesiveness, and plasminogen activator inhibitor-1
PAI-1) production. Cardiac surgery induces additional
omplex hemostatic alterations, triggered by hypothermia,
emodilution, and CPB-induced activation of coagulation,
brinolytic, and inflammatory pathways. Thrombotic out-
omes after cardiac surgery (coronary graft thrombosis,
MI, stroke, pulmonary embolism) represent one extreme
n a continuum of coagulation dysfunction, with coagulopa-
able 2. Representative Genetic Polymorphisms Associated With
Gene Polymorphism
yocardial injury/dysfunction, vein graft failure
IL6 174G/C No
TNFA 308G/A No
IL10 1082G/A Ca
F5 R506Q(FVL) CA
ITGB3 L33P (PlA1/PlA2) CA
m
GP1BA T145M Ma
CMA1 1905A/G CA
erioperative vascular reactivity, coronary tone
NOS3 E298D Ca
ACE In/del Ca
ADRB2 Q27E Tr
GNB3 825C/T -
PON1 Q192R Re
ostoperative atrial fibrillation
IL6 174G/C CA
Be
No
RANTES 403G/A Be
TNFA 308G/A No
ostoperative MACE
ACE In/del CA
ITGB3 L33P CA
MTHFR A222V PT
ADRB2 R16G; Q27E Ca
SELP N562D CA
HP Hp1/Hp2 CA
ardiac allograft rejection
TNFA 308G/A Ca
IL10 1082G/A Ca
IL1RN 86-bp VNTR Th
IL1B 3953C/T Th
ICAM1 K469E Ca
Relative risk; †F value; ‡ coefficient; §in female patients only; in haplotype with
ACE  angiotensin-converting enzyme; ADRB2  2 adrenergic receptor; CABG
VL  factor V Leiden; F5  factor V; GNB3  G-protein-3 subunit; GP1BA 
interleukin-1; IL1RN  interleukin 1 receptor antagonist; IL6  interleukin 6; IL
THFRmethylenetetrahydrofolate reductase; n.r. not reported; NOS3 endoth
pon activation normally T-expressed and secreted; SELP  P-selectin; TNFA  tuhy and bleeding at the other end. Pathophysiologically, the calance between bleeding, normal hemostasis, and throm-
osis is markedly influenced by rate of thrombin formation
nd platelet activation. Genetic variants modulate activity of
ach of these mechanistic pathways (44), suggesting herita-
ility of a prothrombotic state.
Several prothrombotic genotypes are associated with risk
f coronary graft thrombosis and myocardial injury after
ABG. A common prothrombotic point mutation in co-
gulation factor V (factor V Leiden [FVL]) results in resis-
ance to activated protein C and increased risk of myocardial
nfarction (45). In a prospective study of CABG patients
ith routine three-month post-operative angiographic
ollow-up, a higher proportion of FVL carriers had graft
cclusion compared to non-carriers (46).
A platelet glycoprotein IIIa gene (ITGB3) polymorphism,
esulting in increased platelet aggregation, is associated with
igher postoperative troponin I levels (47) and increased
isk for one-year thrombotic coronary graft occlusion, myo-
erse Perioperative Cardiovascular Events
pe of Surgery OR Reference
diac (thoracic) 1.8 (43)
diac (thoracic) 2.5 (43)
CPB n.r. (42)
CPB 3.29 (46)
CPB,
vascular
2.5* (47)
2.4 (15)
scular 3.4 (15)
CPB n.r. (17)
CPB n.r. (50,54)
CPB n.r. (30,51)
l intubation 11.7† (52)
onists n.r. (54)
coronary tone n.r. (54)
CPB 3.25 (16)
cker failure, n.r. (75)
diac (thoracic) 1.8 (43)
cker failure n.r. (75)
diac (thoracic) 2.5 (43)
CPB 3.1‡ (37)
CPB 4.7 (25)
nd CABG/CBP 2.8 (92)
surgery/CPB 1.96; 2.82 (24)
 valve/CPB 18.5§ (93)
n.r. (36)
transplant n.r. (18)
transplant n.r. (18)
transplant 2.02 (94)
transplant 20.5 (94)
transplant n.r. (95)
VNTR.
ronary artery bypass graft; CPB  cardiopulmonary bypass; CMA1  heart chymase;
protein Ib; HP  haptoglobin; ICAM1  intercellular adhesion molecule 1; IL1B
interleukin 10; ITGB3  glycoprotein IIIa; MACE  major adverse cardiac events;
itric oxide synthase; OR odds ratio; PON1 paraoxonase 1; RANTES regulated
ecrosis factor-; VNTR  variable number tandem repeat.Adv
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December 6, 2005:1965–77 Genetics of Perioperative Outcomesndergoing major vascular surgery, two SNPs in platelet
lycoprotein receptors (ITGB3 and GP1BA) are indepen-
ent risk factors for PMI and result in an improved
redictive model when added to historic and procedural risk
actors (15).
able 3. Representative Genetic Polymorphisms Associated With
Gene Polymorphism
erioperative thrombotic events
F5 FVL
erioperative bleeding
F5 R506Q(FVL)
ITGA2 52C/T, 807C/T
GP1BA T145M
TF 603A/G
TFPI 399C/T
F2 20210G/A
ACE In/del
erioperative neurological injury
APOE 4
ITGB3 L33P (PA1/PA2)
IL6 174G/C
CRP 1846C/T(3=UTR)
erioperative acute renal injury
IL6 572G/C
AGT M235T
NOS3 E298D
APOE 4
 coefficient; †F value.
AGT  angiotensinogen; APOE  apolipoprotein E; CRP  C-reactive protein;
athway inhibitor; other abbreviations as in Table 2.
igure 3. The degree of perioperative myocardial injury is a result of the
alance between injurious and cardioprotective (endogenous and exoge-
ous) biological mechanisms, mediated via a wide array of biochemical
athways with extensive genetic variability. AR  adrenergic receptor;
PB  cardiopulmonary bypass; EC  endothelial cells; PMN S
olymorphonuclear neutrophils; RNS  reactive nitrogen species; ROS 
eactive oxygen species.Plasminogen activator inhibitor-1 is an important nega-
ive regulator of fibrinolytic activity; an insertion/deletion
olymorphism in the PAI-1 promoter has been consistently
ssociated with higher plasma levels of PAI-1. A high corre-
ation has been reported between PAI-1 levels and risk of
ngiographically detected early graft thrombosis after CABG
48), and a meta-analysis showed significant effect of PAI-1
enotype on incidence of myocardial infarction (49).
ENETIC POLYMORPHISMS AND PERIOPERATIVE VASCULAR
EACTIVITY. With robust sympathetic nervous system ac-
ivation characteristic of perioperative stress responses, and
nown to play an important role in the pathophysiology of
MI, patients with CAD and specific adrenergic receptor
AR) genetic polymorphisms may be particularly susceptible
o catecholamine toxicity and cardiac complications. Signif-
cantly increased perioperative vascular responsiveness to
lpha-AR stimulation (phenylephrine) is found in carriers
f an endothelial nitric oxide synthase (NOS3) SNP (50)
nd angiotensin-converting enzyme (ACE) insertion/
eletion polymorphism (30,51) undergoing cardiac surgery
ith CPB. A common 2AR variant (ADRB2) is associated
ith increased blood pressure in response to endotracheal
ntubation (52). Several other functionally important poly-
orphisms modulating AR pathways have been character-
zed (for review, see Zaugg and Schaub [53]).
Three functionally important SNPs are specifically asso-
iated with variations in coronary tone (54). A polymor-
hism in GNB3, encoding the G protein 3 subunit, is
ssociated with exaggerated coronary vasoconstrictor re-
ponse to -AR agonists, and a paraoxonase-1 (PON1)
er Adverse Perioperative Outcomes
Type of Surgery OR Reference
on-cardiac, cardiac n.r. (28)
rdiac/CPB 1.25* (27)
BG/CPB 0.15* (26)
BG/CPB 0.22* (26)
BG/CPB 0.03* (26)
BG/CPB 0.05* (26)
BG/CPB 0.38* (26)
BG/CPB 0.15* (26)
BG/CPB n.r. (22)
rdiac/CPB n.r. (21)
rdiac/CPB 3.3 (23)
rdiac/CPB 3.3 (23)
BG/CPB 20.04† (20)
BG/CPB 32.19† (20)
BG/CPB 4.29† (20)
BG/CPB 0.13* (19,20)
prothrombin; ITGA2  glycoprotein IaIIa; TF  tissue factor; TFPI  tissue factorOth
N
Ca
CA
CA
CA
CA
CA
CA
CA
Ca
Ca
Ca
CA
CA
CA
CA
F2 NP is associated with increased coronary vasomotor tone
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Genetics of Perioperative Outcomes December 6, 2005:1965–77t rest. Conversely, a NOS3 SNP is associated with reduced
ndothelium-dependent coronary vasodilation and coronary
pasm. Although some of these associations have not been
irectly validated in the perioperative setting, identification
f polymorphisms modulating interindividual variability in
oronary vasomotor response may have important implica-
ions for prediction of perioperative myocardial ischemic
vents, given the intrinsic catecholamine surges and preva-
ent use of alpha-AR agonists during this period.
ENE EXPRESSION STUDIES OF MYOCARDIAL PRE-
ONDITIONING. Microarray technology has revolutionized
ene expression analysis in complex disease by simulta-
eously examining genome-wide changes of many thou-
ands of mRNA transcripts in a single experiment. Several
tudies have reported gene expression patterns in ischemic
55) and stunned myocardium (56). In perioperative medi-
ine, microarrays have been applied to evaluate organ-
pecific responses to surgical stress, endotoxemia, and CPB
ith cardioplegic arrest (57), which are age-related (58).
mportantly, microarray profiling is being used to search for
ovel cardioprotective genes, with a goal of designing
trategies to activate beneficial pathways and prevent myo-
ardial injury. Pre-conditioning is one such well-studied
odel of cardioprotection, induced by triggers like inter-
ittent ischemia, heat shock, and, interestingly, inhaled
nesthetics. Different transcriptional programs are activated
n ischemic versus anesthetic pre-conditioning, resulting in
istinct cardioprotective phenotypes (59,60). Development
f molecular signatures defining magnitude of myocardial
njury and response to various cardioprotective strategies
ay ultimately contribute to improved outcome prediction
able 4. Summary of Gene Expression Studies With Implication
Tissue (Species) Stimulus/Method
yocardium (rat) Ischemia/A
yocardium (human) CPB; circulatory arrest/A
yocardium (rat) IPC vs. APC/A
yocardium (rat) APC vs. ApostC/A
trial myocardium (pig) Pacing-induced AF/A  P
trial myocardium (human) AF/A
BMC (human) Heart transplant/A
BMC (human) Heart transplant/RT-PCR
yocardium (human) Heart transplant/P
BMC, plasma (human) TAAA/A  P
F  atrial fibrillation; APC  anesthetic preconditioning; APostC  anesthetic po
icroarray; MCL-2  myosin light chain 2; MODS  multiple organ dysfunction
eal-time polymerase chain reaction; TAAA  thoracoabdominal aortic aneurysm ren patients undergoing coronary revascularization (Table 4). aostoperative atrial fibrillation (AF). With a reported
ncidence of 27% to 40%, new-onset postoperative AF
PoAF) remains a common complication of cardiac and
ajor non-cardiac thoracic surgical procedures, associated
ith increased morbidity, hospital length of stay, rehospi-
alization, health care costs, and reduced survival (61,62).
everal large prospective multicenter trials have identified
nd validated comprehensive risk indexes for development
f PoAF based on demographic, clinical, electrocardio-
raphic, and procedural risk factors, but their predictive
ccuracy remains at best moderate (63), suggesting an inher-
nt genetic pre-operative risk. Heritability of AF has been
eported, with genome-wide linkage scans successfully map-
ing genetic loci for familial AF (64) and gain-of-function
utations in cardiac potassium channel genes associated
ith AF (65). It appears that AF is genetically heteroge-
eous (66), with both rare monogenic forms, like “lone” AF,
nd polygenic predisposition to more common acquired
orms (67), like PoAF. Such genetic modifiers interact with
dditional environmental stressors to determine abnormal
ardiac electrical activity and modulate long-term remodel-
ng of cardiac structural and electrical substrates. Candidate
usceptibility genes for PoAF include those determining
ction potential duration (voltage-gated ion channels, ion
ransporters), magnitude of inflammatory and oxidative
tress, responses to extracellular factors (adrenergic and
ther hormone receptors, signal transduction mechanisms,
eat shock response), and remodeling processes (68).
Accumulating evidence suggests a role for inflammation
n the pathogenesis of AF in general (69) and after cardiac
urgery; PoAF is predicted by baseline C-reactive protein
evels (70) and exaggerated postoperative leukocytosis (71),
Perioperative Cardiovascular Outcomes
Genomic Signature:
Number/Types of Genes Reference
14 (wound-healing, Ca-handling) (55)
58 (inflammation, transcription activators,
apoptosis, stress response)–adults
(57)
50 (cardioprotective, antiproliferative,
antihypertrophic)–neonates
(58)
566 differentially regulated/56 jointly
regulated (cell defense)
(59)
Opposing genomic profiles, 8 gene clusters,
2% jointly regulated genes
(60)
81 (MCL-2 ventricular/atrial isoform shift) (84)
1,434 (ventricular-like genomic signature) (85)
30 (profile correlated with biopsy-proven
rejection; persistent immune activation
in response to treatment)
(96)
20 (AlloMap, AlloMap score) (98)
2 (increased B-crystallin and tropomyosin
serum levels)
(103)
138 genes and 7 plasma proteins predicted
MODS
(112)
itioning; CPB  cardiopulmonary bypass; IPC  ischemic preconditioning; A 
rome; P  proteomics; PBMC  peripheral blood mononuclear cells; RTPCR s for
stcondnd prevented by administration of non-steroidal anti-
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December 6, 2005:1965–77 Genetics of Perioperative Outcomesnflammatory drugs (63). The robust inflammatory insult
licited by cardiac surgery with CPB, as well as pericarditis,
lters atrial coupling with transient structural and electrical
hanges that predispose to PoAF (72). Complement acti-
ation and C-reactive protein have been mechanistically
ssociated with PoAF after cardiac surgery (73). A single
tudy has directly examined inflammation gene variants in
elation to PoAF, with a functional SNP in the IL6 promoter
ndependently predicting PoAF after CABG (16). This
olymorphism has consistently shown a strong relationship
ith IL6 plasma levels (38), postoperative inflammatory
omplications (74), and hospital length of stay after cardiac
urgery (39). In a preliminary report, this IL6 variant and a
hemokine, RANTES (Regulated upon Activation, Normally
-Expressed, and presumably Secreted), SNP were shown to
e independent risk factors for failure of beta-blockers in
reventing PoAF (75). Additionally, polymorphisms in two
nflammatory genes (IL6 and TNFA) were associated with
omposite postoperative morbidity (including new-onset
rrhythmias) after lung resection procedures (43).
An important modulator of myocardial fibrosis and re-
odeling, the renin-angiotensin system, is involved in AF,
videnced by increased atrial expression of ACE in patients
ith AF and beneficial effects of ACE inhibitor therapy in
educing AF occurrence associated with myocardial infarc-
ion, left ventricular dysfunction, and relapse rates after
ardioversion. Perioperative ACE inhibitor therapy in car-
iac surgical patients also reduces risk of PoAF, whereas
ithdrawal from therapy increases risk (63). Several associ-
tions between non-familial structural AF and genetic
ariants in the renin-angiotensin system have been reported,
ncluding the ACE insertion/deletion (76), and several
ngiotensinogen (AGT) polymorphisms (77), but none so
ar directly related to PoAF.
Other mechanisms may also be important in AF. Al-
hough associated with altered inward rectifier and
cetylcholine-activated K currents in cultured atrial myo-
ytes, a SNP in 3-subunit of G-proteins (GNB3) shows no
enotypic differences between atrial myocardial tissues from
atients with or without PoAF and no association with
ncidence of PoAF (78). Age-dependent atrial accumulation
f a mitochondrial DNA deletion mutation (mtDNA-
977) is associated with AF (79), providing a possible
xplanation for increased incidence of AF with age. Fur-
hermore, a recent study reported association between mi-
ochondrial dysfunction in response to ischemia-reperfusion
njury and PoAF (80). Heat shock proteins (HSP) are
olecular chaperones that protect during cardiac-surgery-
nduced ischemia-reperfusion myocardial injury. Pre-
perative atrial HSP70 expression levels inversely correlate
ith incidence of PoAF (81), and anti-HSP65 antibodies
re associated with occurrence of PoAF after cardiac surgery
82). Oxidative stress has been implicated as a pathophysi-
logic mechanism in PoAF, with CABG patients demon-
trating increased plasma lipid peroxidation and decreased
ardiac glutathione levels after aortic cross clamp release, (ersisting for 24 h postoperatively. Transcriptional pro-
ling of human atrial myocardium identifies a shift in
alance of pro-oxidation and antioxidation toward oxidative
tress that occurs in AF (83), suggesting antioxidants may
rove to be interesting therapeutic targets for AF.
In a porcine model of pacing-induced AF, integrated
enomic and proteomic analysis of characteristic early myo-
ardial gene expression changes demonstrate increased ra-
ios of ventricular to atrial isoforms in fibrillating atrial
issue, suggesting dedifferentiation (84). These findings were
ecently replicated in humans, with a similar ventricular-like
enomic signature observed in fibrillating atrium (85).
owever, it remains unclear whether “ventricularization” of
trial gene expression reflects cause or effect of AF. Human
ight atrial microarray studies have identified gene expres-
ion signatures highly predictive of PoAF following cardiac
urgery (86). Initial human proteomic studies also identify
pecific PoAF signatures (87), as well as overall down-
egulation of protein expression, which may represent adap-
ive energy-saving processes to the high metabolic demand
f fibrillating atrial myocardium, akin to chronic hiberna-
ion. Elucidating which changes are required for initiation
f AF, or diseases that predispose to AF, is important in
dentifying novel therapeutic targets (88) (Table 4).
Studies summarized in the preceding text illustrate the
omprehensive approaches required to “tackle” complex
henotypes like AF. Future efforts will also need to capture
ene-gene and gene-environment interactions, as well as
arious endophenotypes (electrocardiographic P-wave ab-
ormalities, biomarkers) that co-segregate with AF.
erioperative event-free survival. Several large random-
zed clinical trials have identified subgroups of patients who
enefit from surgical revascularization, yet this group still
emonstrates substantial variability in long-term survival
fter CABG, implicating genetic influences. Increasing evi-
ence suggests that ACE insertion/deletion polymorphism
nfluences post-CABG complications, including higher
ortality and graft restenosis rates (37). Similarly, a func-
ionally important glycoprotein IIb/IIIa platelet receptor
ITGB3) SNP is associated with risk for major adverse
ardiac events (MACE), a composite of myocardial infarc-
ion, coronary bypass graft occlusion, or death after CABG
urgery (25). Mechanistically, this may be related to a
enetically modulated prothrombotic tendency, as this SNP
esults in increased fibrinogen binding and epinephrine-
nduced platelet aggregation (89) and is associated with
cute coronary thrombosis (90). Hyperhomocysteinemia is
nother important risk factor for coronary, cerebrovascular,
nd peripheral vascular atherosclerotic disease, and a strong
redictor of mortality among patients with CAD. Plasma
omocysteine levels are influenced by both environmental
nd genetic factors, with a methylenetetrahydrofolate reduc-
ase gene (MTHFR) SNP influencing enzyme activity,
esulting in elevated plasma homocysteine levels (91). In a
tudy of patients undergoing myocardial revascularization
both percutaneous and surgical), the MTHFR genotype
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Genetics of Perioperative Outcomes December 6, 2005:1965–77redicts MACE (92). Our group recently found preliminary
vidence for association between two functional SNPs
odulating 2AR activity and death/MACE after cardiac
urgery (24). We also reported association between a non-
ynonymous P-selectin (SELP) SNP and risk of MACE
fter combined CABG-valve surgery in women only; this
ay explain some observed gender-based disparities in
ardiac surgery outcomes (93).
enomic profiling and risk of cardiac allograft rejection.
espite increased success of heart/lung transplantation,
evere complications (acute rejection, transplant CAD,
ost-transplant malignancies, infections) continue to result
n morbidity and mortality. A central phenomenon in graft
ejection is a shift of proinflammatory and anti-inflammatory
ytokines away from a graft-tolerant state toward a proin-
ammatory milieu (7); several cytokine gene polymorphisms
ave been associated with allograft outcome (7,18). A
ypersecretor genotype in the TNFA promoter and a
yposecretor genotype in the anti-inflammatory cytokine
L10 promoter increase risk of acute cardiac graft rejection
18). A functional polymorphism in interleukin-1 receptor
ntagonist (IL1RN), an endogenous anti-inflammatory
olecule, is associated with increased frequency of chronic
horacic allograft rejection when combined with specific
L-1 genotypes, particularly when IL1 region haplotypes
nd multiple rejection episodes were investigated (94).
onversely, presence of an intercellular adhesion
olecule-1 (ICAM1) SNP in either donor or recipient is
rotective against transplant vasculopathy (95).
Currently, serial right ventricular endomyocardial biop-
ies are the mainstay for monitoring heart transplant rejec-
ion; biopsies are invasive and limited by patient discomfort,
isk of complications, poor reproducibility, and cost. A
oninvasive strategy, peripheral blood gene expression pro-
ling in circulating leukocytes, has been correlated with
iopsy-proven allograft rejection (96). Using oligonucleo-
ide microarrays, a characteristic genomic signature of acute
ellular rejection has been identified that can reveal persis-
ent immune activation despite normalization of biopsy in
esponse to treatment. This suggests expression profiling
ay provide more sensitive screening for rejection (96). The
rospective multicenter Cardiac Allograft Rejection Gene
xpression Observational (CARGO) study was designed to
evelop and validate a gene expression test for detection and
onitoring of acute rejection and quiescence in cardiac
ransplant recipients using peripheral blood mononuclear
ells. After an exploratory phase (candidate gene identifica-
ion using microarray analysis) (97), in the development
hase (98) a 20-gene real-time quantitative polymerase
hain reaction assay (AlloMap, XDx, South San Francisco,
alifornia) was used in conjunction with an algorithm to
ield a score (AlloMap score) that reliably and reproducibly
istinguishes quiescence from acute rejection (99); these
ndings have been subsequently validated in an independent
atient population. Such technology may help tailor steroid
herapy to avoid over-immunosuppression, thus minimizing mnfectious and malignant long-term complications (100)
nd resulting in significant health care savings (101). An-
ther technology that has been used to investigate cell-based
nflammatory responses in heart transplantation is the leu-
ocyte antibody array. Increased expression of specific leu-
ocyte cluster of differentiation antigens has been reported
uring CPB in patients undergoing heart transplantation
102). Furthermore, using a proteomic approach, two myo-
ardial proteins (B-crystallin and tropomyosin) have been
dentified as significantly increased in sera of patients
howing histological signs of rejection (103). However, it is
ikely that a panel of protein markers will be required to
rovide enough sensitivity to detect all rejection episodes.
dverse perioperative neurologic outcomes. Despite ad-
ances in surgical and anesthetic techniques, significant
eurologic morbidity continues to occur after cardiac sur-
ery, ranging in severity from coma and focal stroke (inci-
ence up to 6%) to more subtle cognitive deficits (incidence
p to 69%), with substantial impact on risk of perioperative
eath, quality of life, and resource utilization. Cardiac surgery
epresents a unique clinical paradigm where, in addition to
enetic predispositions, certain procedural events (such as
ortic manipulation) may lead to embolization of material to
he brain and perioperative neurological injury, the patho-
hysiology of which involves complex interactions between
rimary pathways associated with atherosclerosis and
hrombosis, and secondary response pathways like inflam-
ation, oxidative stress, vascular reactivity, and direct cel-
ular injury. Functional genetic variants have been described
n each of these mechanistic pathways. Our group reported
n association of APOE genotype with adverse cerebral
utcomes in cardiac surgery patients (22), consistent with
ther studies suggesting a role for APOE variants in recovery
rom acute brain injury such as intracranial hemorrhage,
losed head injury, stroke, and experimental models of
erebral ischemia-reperfusion injury (for review, see New-
an et al. [104]). Unlike adult patients, infants carrying a
ifferent APOE isoform are at risk for developing adverse
eurodevelopmental sequelae after cardiac surgery (105).
echanistically, the role of APOE genotypes in modulating
nflammatory response (40), extent of aortic atheroma
urden (106), risk for coronary atherosclerosis (107), and
utoregulation of cerebral blood flow may explain the
bserved associations with altered neurological outcomes.
Platelet activation is a centerpiece in the pathophysiology
f adverse neurological sequelae. Genetic variants in surface
latelet membrane glycoproteins, important mediators of
latelet adhesion and platelet-platelet interactions, increase
usceptibility to prothrombotic events. Among these an
TGB3 polymorphism related to various adverse thrombotic
utcomes, including acute coronary thrombosis (90) and
therothrombotic stroke (108), is also correlated with neu-
ocognitive decline after CPB (21), potentially representing
xacerbation of platelet-dependent thrombotic processes
ssociated with plaque embolism. We identified two com-
on SNPs in the promoter region of IL6 and 3=-untranslated
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December 6, 2005:1965–77 Genetics of Perioperative Outcomesegion of C-reactive protein (CRP) genes as independent
redictors of stroke risk after cardiac surgery, suggesting a
ivotal role of inflammation in the pathogenesis of periop-
rative stroke (23), and consistent with an increasing body
f literature identifying proinflammatory genetic profiles as
usceptibility factors in stroke (109).
Implications of identifying novel predictors for risk of
erioperative neurological dysfunction and the molecular
echanisms underlying such risk are several-fold. Patient-
nformed consent process will be improved, and resource
llocation can be optimized based on risk stratification.
econd, development of neuroprotective agents, and appli-
ation of therapeutic modalities tailored to an individual’s
olecular risk profile, will be facilitated.
ntegrating “omic” information. Integrated genomic and
roteomic analysis have been applied to characterize tissue-
pecific adaptive and maladaptive programs of gene expres-
ion in animal models of surgical stress (110) and myocar-
ial ischemia-reperfusion injury (111), and to predict outcome
n patients undergoing thoracoabdominal aortic aneurysm
epair. Gene expression patterns from peripheral blood
eukocytes and circulating plasma proteins discriminated
etween patients who developed multiple organ dysfunction
yndrome and those who did not (112).
The metabolic consequences of surgery and anesthesia are
omplex. Surgical trauma triggers an integrated neuroendo-
rine reaction, with increased secretion of stress hormones,
ntidiuretic hormone, and activation of the renin-angiotensin
ystem. The magnitude of the ensuing counter-regulatory
esponse depends on the severity of surgery and postoperative
omplications, such as sepsis, but perioperative hyperglycemia-
nsulin resistance appears to be related to various postoperative
dverse events, especially after cardiac surgery. Thus, periop-
rative assessment of an individual’s metabolic state using
etabolomic techniques (the global study of all molecules
roduced in the human body) can help clinicians understand
omplex metabolic derangements associated with surgical
tress. One principal advantage metabolomics offers over other
omic” technologies such as transcriptomics and proteomics is
hat metabolic information is readily transferable between
pecies. Preliminary studies have reported using metabolic
ignatures to characterize overall effects of stress (113), impact
f ischemia-reperfusion injury on allograft function (114), and
ffectiveness of cytoprotective therapy in preventing lung injury
n models of surgical sepsis (115) or myocardial ischemia-
eperfusion injury (116).
ERIOPERATIVE CLINICAL GENOMICS:
IPE DREAM OR NEAR REALITY?
n this review, opportunities to use the unique operating
oom environment to answer potentially important and
linically relevant physiologic questions have been pre-
ented. Indeed, this process gives new meaning to the
perating room as the “last human physiology laboratory in bedicine.” Perioperative physicians have long recognized
hat a bell-shaped curve of responses occurs to various
nvironmental perturbations (inflammatory response to
tress of surgery, hemodynamic challenge, drug administra-
ion, and so on) demonstrating that although most patients
espond in predictable patterns, others respond either more
r less vigorously. Astute clinicians appreciate that an
ndividual patient’s response to stress may alter perioperative
utcomes such as incidence of PMI, arrhythmias, respiratory
istress syndrome, survival, and response to pain management.
ut what are the mechanisms underlying physiologic and
harmacodynamic variability to stress? The answer to this
omplex question includes understanding how the unique
enetic background an individual brings to the operating
oom affects his or her perioperative outcome. It is becom-
ng increasingly clear that although proinflammatory path-
ays are important in wound healing in the perioperative
nd intensive care unit environment, too robust of a response
ay be detrimental, resulting in poorer patient outcome.
obust activation of proinflammatory pathways appears to
ugment organ injury by providing a milieu that goes
eyond normal healing of a surgical incision, trauma, or
evere illness, to induce injury. Thus, in the context of the
xtreme acute perioperative (environmental) stressors, ge-
etically modulated deficiencies in homeostatic mechanisms
re unmasked and may contribute to adverse postoperative
ardiovascular outcomes.
As studies are now published suggesting perioperative
rgan injury can be predicted by examining genetic variabil-
ty, how can this information be translated to the clinic once
alidated? Is it possible to stratify patients so that increased
isk for myocardial injury, stroke, bleeding, renal complica-
ions, sepsis, and neurocognitive deficits can be determined
efore surgery? The answer to this question is—yes. The
bility to rapidly genotype large numbers of patients for
alidated genetic variants is becoming reality. However,
efore being considered in clinical perioperative risk man-
gement, genomic-based tests will need to have additional
redictive power over and above accepted risk factors (117).
e, and others, have already identified genetic variants
hat, when evaluated simultaneously, improve the predict-
bility of existing models of perioperative adverse events
20,23,26). Because the effect size of any single genetic
ariant on the clinical end points is relatively modest, it is
he multilocus interaction of several genotypes that will
ikely be large enough to be of clinical relevance. Thus,
urther progress in analysis of complex traits, including
erioperative cardiovascular complications, will require si-
ultaneous analysis of increasingly larger numbers of ge-
etic variants in a highly systematic and unbiased fashion,
hile balancing the increased informativity of such an
pproach against costs and the challenges it imposes on
enetic epidemiology and computational biology. Further-
ore, the turn-around time from taking a blood sample and
aving a genetic “fingerprint” should be 12 h in order to
e clinically useful, ideally just a few hours (much like
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Genetics of Perioperative Outcomes December 6, 2005:1965–77linical chemistries are analyzed now). This will become
eality over the next few years using many genotyping
latforms. A panel of SNPs replicated in different indepen-
ent patient populations and validated by functional
enomics approaches will likely be used in the near future as
“perioperative chip” to predict risks of adverse events and
rug responses in patients undergoing major surgery.
The operating room is very receptive to new technologies,
eing the incubator of many patient-monitoring modalities
nd surgical devices. Hence, it is no surprise that several
enomic-based tests have already been implemented clini-
ally and have the potential to impact perioperative man-
gement. We have already described the AlloMap (XDx),
sed to diagnose cardiac allograft rejection and to help tailor
mmunosuppressive therapy postoperatively. The Ampli-
hip CYP450 (Roche Diagnostics, Basel, Switzerland) is a
icroarray-based pharmacogenomics test designed to iden-
ify genetic variants in two major drug metabolizing en-
ymes (CYP2D6 and CYP2C19) and to predict associated
nzyme activities. Because several drugs routinely used in
he perioperative period are metabolized through these
nzymes (beta-blockers, benzodiazepines, anti-emetics),
uch information can aid perioperative physicians to indi-
idualize treatment doses and reduce variability or toxicity
n response to these drugs.
But determining a genetic profile is only the first part of
he equation for clinical utility. The interpretation of spe-
ific combinations of SNPs or gene expression patterns will
e equally important. It is difficult for the average clinician
o stay abreast of all important genetic variants, so interpre-
ations of genetic panels should be simple and suggest
pecific possible interventions (updated regularly) if a pa-
ient is found to be high risk. This will not only facilitate
ovement of genetics into the clinical setting, but should
elp standardize interventions designed to lower risk. It is
lso important to communicate to a patient that just because
hey are determined to be in a low-risk group this does not
ean they will not have an adverse event, just a lower risk
or that event. The introduction of sequence-based infor-
ation into daily clinical practice will lead to an exquisite
re-operative identification of the vulnerable patient, and
uch subtle distinctions will become important in all aspects
f perioperative care, from disclosing perioperative or
eriprocedure risks between physicians and patients, to
re-operative optimization and postoperative monitoring,
hus optimizing the allocation of finite resources to priori-
ized clinical needs. Such “omic”-based decision tools could
e applied for instance in the individualized selection of
rocedure type (e.g., percutaneous vs. surgical on-pump/off-
ump coronary revascularization, catheter-based vs. Maze
rocedure for arrhythmia ablation), intraoperative decisions
e.g., choice of coronary bypass conduit), and postoperative
ollow-up (e.g., anticoagulation management, frequency of
oronary graft surveillance).
A strong need remains for prospective, well-powered
enetic studies in highly phenotyped surgical populations,hich mandate the development of multidimensional peri-
perative databases and establishing perioperative research
onsortia and standardized protocols for biological specimen
ollection and processing as well as phenotype definition.
xisting animal models of perioperative stress and injury
ill continue to be improved, and comparative genomics
pproaches will be used to identify evolutionarily conserved
tress-specific genes and pathways, as well as tissue-specific
rthologous markers that may facilitate early detection of
erioperative organ dysfunction. Molecular profiling will
lso be used in translational drug development and to
dentify patients that respond better to a treatment arm than
he other, providing the scientific basis for improved clinical
rial design and analysis. Furthermore, characterizing the
enomic determinants of drug resistance (e.g., beta-blockers
nd PoAF, aspirin, and vein graft failure) and monitoring
rug responses according to pharmacogenomic principles
ill likely result in individualized drug selection and dosing
or each patient to minimize adverse effects. New anti-
nflammatory, antithrombotic, antioxidant, and cytoprotec-
ive therapeutics will be delivered in the acute setting using
ell-based and genomic-based (e.g., ribonucleic acid inter-
erence, antisense nucleotides) technologies, in addition to
he traditional pharmacological agents.
onclusions. Sequencing of the human genome represents
he pinnacle of a reductionist era in molecular medicine.
he great challenge in coming years is reintegrating this
nformation using systems biology approaches to provide a
etter understanding of the intact organism, its responses to
arious environmental stimuli, and translating the knowl-
dge into daily clinical practice. For the perioperative physi-
ian, this will soon translate into prospective risk assessment
ased on genomic profiling of markers important in inflam-
atory, thrombotic, neurologic, and vascular responses to
erioperative stress, allowing the development of more
omprehensive cross-disciplinary treatment paradigms for
tress-induced organ dysfunction in each individual patient.
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